Literature DB >> 16641465

Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.

Aeron C Hurt1, Pina Iannello, Kim Jachno, Naomi Komadina, Alan W Hampson, Ian G Barr, Jennifer L McKimm-Breschkin.   

Abstract

An influenza B virus from an infant with no history of treatment or contact with neuraminidase inhibitors demonstrated a significant reduction in sensitivity to these drugs. Here, we describe the analysis of a mixed viral population that contained a novel D197E amino acid substitution that was responsible for this reduction.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16641465      PMCID： PMC1472236          DOI： 10.1128/AAC.50.5.1872-1874.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor.

Authors:  J N Varghese; J L McKimm-Breschkin; J B Caldwell; A A Kortt; P M Colman
Journal:  Proteins       Date:  1992-11

2.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

Review 3.  Treatment of influenza with neuraminidase inhibitors: virological implications.

Authors:  N A Roberts
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

4.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

Authors:  L V Gubareva; L Kaiser; M N Matrosovich; Y Soo-Hoo; F G Hayden
Journal:  J Infect Dis       Date:  2001-01-11       Impact factor: 5.226

5.  Resistant influenza A viruses in children treated with oseltamivir: descriptive study.

Authors:  Maki Kiso; Keiko Mitamura; Yuko Sakai-Tagawa; Kyoko Shiraishi; Chiharu Kawakami; Kazuhiro Kimura; Frederick G Hayden; Norio Sugaya; Yoshihiro Kawaoka
Journal:  Lancet       Date:  2004 Aug 28-Sep 3       Impact factor: 79.321

6.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

Authors:  J A L Ives; J A Carr; D B Mendel; C Y Tai; R Lambkin; L Kelly; J S Oxford; F G Hayden; N A Roberts
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

7.  Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.

Authors:  Aeron C Hurt; Ian G Barr; Gunter Hartel; Alan W Hampson
Journal:  Antiviral Res       Date:  2004-04       Impact factor: 5.970

8.  Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.

Authors:  J Carr; J Ives; L Kelly; R Lambkin; J Oxford; D Mendel; L Tai; N Roberts
Journal:  Antiviral Res       Date:  2002-05       Impact factor: 5.970

9.  Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.

Authors:  Larisa V Gubareva
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

10.  The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid.

Authors:  W P Burmeister; R W Ruigrok; S Cusack
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598
View more
  22 in total

Review 1.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

2.  Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.

Authors:  Susan Barrett; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2014-05-20       Impact factor: 5.970

3.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

4.  Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.

Authors:  Mitsutaka Kitano; Yasushi Itoh; Makoto Kodama; Hirohito Ishigaki; Misako Nakayama; Hideaki Ishida; Kaoru Baba; Takahiro Noda; Kenji Sato; Yoichiro Nihashi; Takushi Kanazu; Ryu Yoshida; Ryuzo Torii; Akihiko Sato; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

5.  Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.

Authors:  Henju Marjuki; Vasiliy P Mishin; Anton P Chesnokov; Juan A De La Cruz; Charles T Davis; Julie M Villanueva; Alicia M Fry; Larisa V Gubareva
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

Review 6.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

7.  Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

Authors:  Aaron J Oakley; Susan Barrett; Thomas S Peat; Janet Newman; Victor A Streltsov; Lynne Waddington; Takehiko Saito; Masato Tashiro; Jennifer L McKimm-Breschkin
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

8.  Influenza virus resistance to antiviral agents: a plea for rational use.

Authors:  Gregory A Poland; Robert M Jacobson; Inna G Ovsyannikova
Journal:  Clin Infect Dis       Date:  2009-05-01       Impact factor: 9.079

9.  Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Authors:  Henju Marjuki; Vasiliy P Mishin; Katrina Sleeman; Margaret Okomo-Adhiambo; Tiffany G Sheu; Lizheng Guo; Xiyan Xu; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

10.  Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane.

Authors:  T N Figueira; M T Augusto; K Rybkina; D Stelitano; M G Noval; O E Harder; A S Veiga; D Huey; C A Alabi; S Biswas; S Niewiesk; A Moscona; N C Santos; M A R B Castanho; M Porotto
Journal:  Bioconjug Chem       Date:  2018-09-14       Impact factor: 4.774
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.